Op-Ed: The best way to capitalize on the potential revenue influx from enterprise-level drug adherence programs is to create room at the executive table for a Chief Adherence Officer.
Tom Kottler
Advertisement
Tom Kottler is co-founder and Chief Executive Officer of HealthPrize Technologies, the leading digital adherence and patient engagement platform for life science companies. Kottler has led multiple high-growth organizations during his career, including Advanced BioHealing, which was acquired by Shire for $750 million, and MedAptus, an innovative healthcare IT company based in Boston, Mass.
Articles by Tom Kottler
Outside of raising prices, pharma can generate new revenue from just three other sources, write Tom Kottler.
Addressing adherence with c-suite sponsorship and at scale has the capacity increase revenue, improve patient outcomes and lower health care costs, writes Tom Kottler.
Advertisement
Latest Updated Articles
Adherence: Addressing Pharma's Last-Mile ProblemPublished: June 5th 2018 | Updated: November 15th 2020
- Time is Running Out for Pharma to Change Course
Published: April 1st 2019 | Updated: February 13th 2025
It’s Time for a Chief Adherence OfficerPublished: May 8th 2019 | Updated: November 15th 2020
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
2
Leading in the Psychedelic Space: Q&A with Tarek Rabah
3
Bringing HIV Prevention DTC: Q&A with Ashley Gildea
4
Boehringer Ingelheim Acquires Exclusive License from Sitryx Therapeutics for Preclinical Small Molecule Program
5